Novartis AG has announced positive results from Phase III FLAME trial examining the rate of COPD exacerbations.
In the FLAME study, once-daily Ultibro Breezhaler met primary endpoint and demonstrated superiority to Seretide in reducing COPD exacerbations during 52 weeks of treatment.
FLAME was a randomized, double-blind, parallel-group, non-inferiority, active-controlled 52-week study involving 3,362 COPD patients and conducted at 356 sites across 43 countries.
The first large-scale study confirmes that Ultibro Breezhaler is an effective steroid-free option that both reduces exacerbations and improves lung function in COPD patients with one or more exacerbations in the past year, compared to Seretide, the company said.
View the full story at www.nasdaq.com
